SuperworthEntera Bio EPS ENTX
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- $0.22
- Latest quarter, Q2 FY26
- $0.14
- +133% on a year earlier
- Fiscal year 2025
- $0.13
- +0% on the year before
Entera Bio's earnings per share was $0.22 over the twelve months to Jun 30, 2026, up 57% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.14, up 133% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.13 | +0% |
| FY2024 | $0.13 | −24% |
| FY2023 | $0.17 | −29% |
| FY2022 | $0.24 | +41% |
| FY2021 | $0.17 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.14 | +133% | $0.22 | |
| Q1 FY26 | $0.07 | +17% | $0.14 | |
| Q4 FY25 | −$0.06 | n/a | $0.13 | |
| Q3 FY25 | $0.07 | −13% | $0.13 | |
| Q2 FY25 | $0.06 | +0% | $0.14 | |
| Q1 FY25 | $0.06 | +20% | $0.14 | |
| Q4 FY24 | −$0.06 | n/a | $0.13 | |
| Q3 FY24 | $0.08 | +0% | $0.12 | |
| Q2 FY24 | $0.06 | −25% | $0.12 | |
| Q1 FY24 | $0.05 | −38% | $0.14 | |
| Q4 FY23 | −$0.07 | n/a | $0.17 | |
| Q3 FY23 | $0.08 | −27% | $0.13 |
Against its peers
Companies in Biotechnology nearest Entera Bio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ENTXEntera Bio | $0.22 | +57% a year |
| MGTXMeiraGTx | $0.71 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
Where Entera Bio ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Entera Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.